Mirae Asset Global Investments
INSY

Mirae Asset Global Investments’s Insys Therapeutics, Inc. INSY Stock Holding History

Mirae Asset Global Investments’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,470,996
Closed -$14.2M – 784
2017
Q4 		$14.2M Buy
1,470,996
+437,313
+42% +$2.86M 0.19% 91
2017
Q3 		$9.18M Buy
1,033,683
+399,682
+63% +$4.12M 0.17% 108
2017
Q2 		$8.02M Buy
+634,001
New +$7.5M 0.14% 112

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mirae Asset Global Investments's INSY Position: Q1 2018 in Review

Mirae Asset Global Investments sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 1,470,996 shares — an estimated $14.2M sold.

Mirae Asset Global Investments first reported a position in INSY in Q2 2017 and held it in 3 quarters. The position peaked at $14.2M in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Mirae Asset Global Investments reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Mirae Asset Global Investments sold 1,470,996 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $14.2M.
  • Mirae Asset Global Investments first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Mirae Asset Global Investments's Insys Therapeutics, Inc. position peaked at $14.2M in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Mirae Asset Global Investments's 13F filing for Q1 2018, filed 10 May 2018.